Patents by Inventor Hidekazu Tokuhara

Hidekazu Tokuhara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic amide compounds having an RORvt inhibitory action
    Patent number: 11851449
    Abstract: The present invention relates to compound (I) or a salt thereof which has a ROR?t inhibitory action. In the formula (I), each symbol is as defined in the specification.
    Type: Grant
    Filed: May 10, 2021
    Date of Patent: December 26, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Satoshi Yamamoto, Junya Shirai, Mitsunori Kono, Yoshihide Tomata, Ayumu Sato, Atsuko Ochida, Yoshiyuki Fukase, Shoji Fukumoto, Tsuneo Oda, Hidekazu Tokuhara, Naoki Ishii, Yusuke Sasaki
  • NITROGEN CONTAINING HETEROCYCLES AS CDK12 INHIBITORS
    Publication number: 20230117295
    Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: December 6, 2022
    Publication date: April 20, 2023
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Koji ONO, Masahiro ITO, Toshio TANAKA, Moriteru ASANO, Takaharu HIRAYAMA, Jun FUJIMOTO, Nobuki SAKAUCHI, Yasuhiro HIRATA, Akinori TOITA, Nao MORISHITA, Hironori KOKUBO, Yasuhiro IMAEDA, Hironobu MAEZAKI, Douglas Robert CARY, Ryo MIZOJIRI, Nobuo CHO, Hiroshi BANNO, Hidekazu TOKUHARA, Yasuyoshi ARIKAWA
  • Heterocyclic compound
    Patent number: 11584737
    Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: February 21, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Koji Ono, Masahiro Ito, Toshio Tanaka, Moriteru Asano, Takaharu Hirayama, Jun Fujimoto, Nobuki Sakauchi, Yasuhiro Hirata, Akinori Toita, Nao Morishita, Hironori Kokubo, Yasuhiro Imaeda, Hironobu Maezaki, Douglas Robert Cary, Ryo Mizojiri, Nobuo Cho, Hiroshi Banno, Hidekazu Tokuhara, Yasuyoshi Arikawa
  • Substituted pyrido[1,2-a]pyrimidines and pyrazino[1,2-a]pyrimidines for enhancing AMPA receptor function
    Patent number: 11407748
    Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: August 9, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shinji Nakamura, Satoshi Mikami, Tomoaki Hasui, Tohru Yamashita, Shinji Morimoto, Hidekazu Tokuhara, Norio Oyabu, Masami Yamada, Atsuko Ochida, Kazuaki Takami, Xin Liu
  • Heterocyclic compound
    Patent number: 11274101
    Abstract: The present invention provides a compound having an MAGL inhibitory action, and expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: March 15, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Makoto Kamata, Hideyuki Sugiyama, Minoru Nakamura, Masataka Murakami, Shuhei Ikeda, Tomohiro Okawa, Hidekazu Tokuhara
  • HETEROCYCLIC COMPOUND
    Publication number: 20220048916
    Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.
    Type: Application
    Filed: November 27, 2019
    Publication date: February 17, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Takaharu Hirayama, Yoshiteru Ito, Hiroshi Banno, Hidekazu Tokuhara, Toshio Tanaka, Yasuyoshi Arikawa, Noriyuki Nii, Youichi Kawakita, Shinichi Imamura
  • Heterocyclic compound
    Patent number: 11242348
    Abstract: The present invention provides a compound having an MAGL inhibitory action, and expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: February 8, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Makoto Kamata, Hideyuki Sugiyama, Minoru Nakamura, Masataka Murakami, Shuhei Ikeda, Tomohiro Okawa, Hidekazu Tokuhara
  • Heterocyclic compound
    Patent number: 11230545
    Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: January 25, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takaharu Hirayama, Yoshiteru Ito, Hiroshi Banno, Hidekazu Tokuhara, Toshio Tanaka, Yasuyoshi Arikawa, Noriyuki Nii, Youichi Kawakita, Shinichi Imamura
  • HETEROCYCLIC COMPOUND
    Publication number: 20210363130
    Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: March 28, 2019
    Publication date: November 25, 2021
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Koji ONO, Masahiro ITO, Toshio TANAKA, Moriteru ASANO, Takaharu HIRAYAMA, Jun FUJIMOTO, Nobuki SAKAUCHI, Yasuhiro HIRATA, Akinori TOITA, Nao MORISHITA, Hironori KOKUBO, Yasuhiro IMAEDA, Hironobu MAEZAKI, Douglas Robert CARY, Ryo MIZOJIRI, Nobuo CHO, Hiroshi BANNO, Hidekazu TOKUHARA, Yasuyoshi ARIKAWA
  • HETEROCYCLIC COMPOUND
    Publication number: 20210332045
    Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.
    Type: Application
    Filed: July 2, 2021
    Publication date: October 28, 2021
    Inventors: Takaharu Hirayama, Yoshiteru Ito, Hiroshi Banno, Hidekazu Tokuhara, Toshio Tanaka, Yasuyoshi Arikawa, Noriyuki Nii, Youichi Kawakita, Shinichi Imamura
  • AMIDE COMPOUND
    Publication number: 20210277030
    Abstract: The present invention relates to compound (I) or a salt thereof which has a ROR?t inhibitory action. In the formula (I), each symbol is as defined in the specification.
    Type: Application
    Filed: May 10, 2021
    Publication date: September 9, 2021
    Inventors: Satoshi Yamamoto, Junya Shirai, Mitsunori Kono, Yoshihide Tomata, Ayumu Sato, Atsuko Ochida, Yoshiyuki Fukase, Shoji Fukumoto, Tsuneo Oda, Hidekazu Tokuhara, Naoki Ishii, Yusuke Sasaki
  • Heterocyclic amide compounds having RORyT inhibitory action
    Patent number: 11053262
    Abstract: The present invention relates to compound (I) or a salt thereof which has a ROR?t inhibitory action. In the formula (I), each symbol is as defined in the specification.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: July 6, 2021
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Satoshi Yamamoto, Junya Shirai, Mitsunori Kono, Yoshihide Tomata, Ayumu Sato, Atsuko Ochida, Yoshiyuki Fukase, Shoji Fukumoto, Tsuneo Oda, Hidekazu Tokuhara, Naoki Ishii, Yusuke Sasaki
  • HETEROCYCLIC COMPOUND
    Publication number: 20200270243
    Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: October 4, 2018
    Publication date: August 27, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shinji NAKAMURA, Satoshi MIKAMI, Tomoaki HASUI, Tohru YAMASHITA, Shinji MORIMOTO, Hidekazu TOKUHARA, Norio OYABU, Masami YAMADA, Atsuko OCHIDA, Kazuaki TAKAMI, Xin LIU
  • HETEROCYCLIC COMPOUND
    Publication number: 20200255439
    Abstract: The present invention provides a compound having an MAGL inhibitory action, and expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Application
    Filed: September 27, 2018
    Publication date: August 13, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Makoto KAMATA, Hideyuki SUGIYAMA, Minoru NAKAMURA, Masataka MURAKAMI, Shuhei IKEDA, Tomohiro OKAWA, Hidekazu TOKUHARA
  • Heterocyclic compound
    Patent number: 10610520
    Abstract: The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: April 7, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shuhei Ikeda, Hideyuki Sugiyama, Jumpei Aida, Hidekazu Tokuhara, Tomohiro Okawa, Yuya Oguro, Minoru Nakamura, Masataka Murakami
  • AMIDE COMPOUND
    Publication number: 20200010487
    Abstract: The present invention relates to compound (I) or a salt thereof which has a ROR?t inhibitory action. In the formula (I), each symbol is as defined in the specification.
    Type: Application
    Filed: September 19, 2019
    Publication date: January 9, 2020
    Inventors: Satoshi Yamamoto, Junya Shirai, Mitsunori Kono, Yoshihide Tomata, Ayumu Sato, Atsuko Ochida, Yoshiyuki Fukase, Shoji Fukumoto, Tsuneo Oda, Hidekazu Tokuhara, Naoki Ishii, Yusuke Sasaki
  • Amide compound
    Patent number: 10472376
    Abstract: The present invention relates to compound (I) or a salt thereof which has a ROR?t inhibitory action. In the formula (I), each symbol is as defined in the specification.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: November 12, 2019
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Satoshi Yamamoto, Junya Shirai, Mitsunori Kono, Yoshihide Tomata, Ayumu Sato, Atsuko Ochida, Yoshiyuki Fukase, Shoji Fukumoto, Tsuneo Oda, Hidekazu Tokuhara, Naoki Ishii, Yusuke Sasaki
  • Heterocyclic compound
    Patent number: 10323026
    Abstract: The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: June 18, 2019
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Shuhei Ikeda, Hideyuki Sugiyama, Jumpei Aida, Hidekazu Tokuhara, Tomohiro Okawa, Yuya Oguro, Minoru Nakamura, Masataka Murakami
  • HETEROCYCLIC COMPOUND
    Publication number: 20190125728
    Abstract: The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: March 30, 2017
    Publication date: May 2, 2019
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shuhei IKEDA, Hideyuki SUGIYAMA, Jumpei AIDA, Hidekazu TOKUHARA, Tomohiro OKAWA, Yuya OGURO, Minoru NAKAMURA, Masataka MURAKAMI
  • HETEROCYCLIC COMPOUND
    Publication number: 20180319812
    Abstract: The present invention relates to compound (I) or a salt thereof which has a ROR?t inhibitory action. wherein each symbol is as defined in the specification.
    Type: Application
    Filed: July 13, 2018
    Publication date: November 8, 2018
    Inventors: Satoshi Yamamoto, Junya Shirai, Hiroyuki Watanabe, Shoji Fukumoto, Tsuneo Oda, Hidekazu Tokuhara, Yoshihide Tomata, Naoki Ishii, Michiko Tawada, Mitsunori Kono, Atsuko Ochida, Takashi Imada, Yoshiyuki Fukase, Tomoya Yukawa